0LDR.L
Teladoc Health Inc
Q3 2025 Report
Teladoc Health Inc (0LDR.L) QQ3 2025 Financial Analysis and Investor Outlook...
Read full report
Executive Summary
Teladoc Health reported Q4 2024 revenue of $640.5 million, flat QoQ and down 3.0% year over year, with gross profit of $451.6 million and a gross margin of 70.5%. The company posted an operating loss of $48.2 million and a net loss of $48.4 million, translating to an EPS of -$0.28. EBITDA reached $11.8 million, yielding an EBITDA margin of roughly 1.8%. Notwithstanding the negative GAAP profitability, Teladoc generated positive operating cash flow of $85.9 million and free cash flow of $56.3 million, supported by favorable working capital movements and depreciation/al compensation. Cash at end of period stood at $1.299 billion, with total debt of $1.585 billion and net debt of $286 million, leaving the balance sheet relatively liquid for ongoing investments and debt service.
Key Performance Indicators
Revenue
640.49M
QoQ: 0.00% | YoY:-3.03%
Gross Profit
451.56M
70.50% margin
QoQ: -2.00% | YoY:-3.33%
Operating Income
-48.22M
QoQ: -8.59% | YoY:44.67%
Net Income
-48.41M
QoQ: -45.48% | YoY:-67.56%
EPS
-0.28
QoQ: -40.00% | YoY:-64.71%
Revenue Trend
Margin Analysis
Key Insights
Revenue: $640.5m; YoY -3.03%, QoQ 0.00% ...